The Corporation focussed on the biology of healing this week released Q3 numbers which reflected the benefits of the first deal for its small molecule division recognising $19.7m of funding due from Shenzen Royal Asset Management. We had previously expected a similar quantum as a balance sheet item. We have therefore increased our FY2017 revenue expectation from $20m to $35.5m and have reduced our forecast net loss from $130.9m to $115.9m. Despite the expansion of the clinical program R&D
16 Nov 2017
Q3 revenues push ahead. Costs under control. Significant commercial and clinical milestones ahead
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Q3 revenues push ahead. Costs under control. Significant commercial and clinical milestones ahead
ProMetic Life Sciences (PLI:TSE) | 0 0 1.3% | Mkt Cap: 1,075m
- Published:
16 Nov 2017 -
Author:
Derren Nathan -
Pages:
6
The Corporation focussed on the biology of healing this week released Q3 numbers which reflected the benefits of the first deal for its small molecule division recognising $19.7m of funding due from Shenzen Royal Asset Management. We had previously expected a similar quantum as a balance sheet item. We have therefore increased our FY2017 revenue expectation from $20m to $35.5m and have reduced our forecast net loss from $130.9m to $115.9m. Despite the expansion of the clinical program R&D